keyword
MENU ▼
Read by QxMD icon Read
search

sacubitril, valsartan

keyword
https://www.readbyqxmd.com/read/30324615/troponin-i-levels-as-a-potential-prognostic-biomarker-of-sacubitril-valsartan-treatment-response-in-heart-failure-with-reduced-ejection-fraction-who-will-benefit-most
#1
Eleni S Nakou, Maria E Marketou, Gregory I Chlouverakis, Alexandros P Patrianakos, Panos E Vardas, Fragiskos I Parthenakis
BACKGROUND: Despite robust data on the benefits of sacubitril/ valsartan (LCZ696) in patients with chronic heart failure with reduced ejection fraction (HFrEF), there is no evidence yet on prespecified predictive markers of its efficacy. HYPOTHESIS: The objective of this study was to identify potentially prognostic factors of LCZ696 treatment response. METHODS: We included 48 symptomatic patients with chronic HFrEF (LVEF ≤ 35%) and New York Heart Association (NYHA) class II/III: Group A (N =23) received LCZ696 (105 ± 30 mg twice daily), whereas it was not prescribed in group B (N = 25) according to physician's judgement...
October 15, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/30320726/is-sacubitril-valsartan-safe-for-treatment-of-hypertension-at-any-age
#2
Renato De Vecchis, Carmelina Ariano
No abstract text is available yet for this article.
October 12, 2018: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/30281045/-anmco-position-paper-on-sacubitril-valsartan-in-the-management-of-patients-with-heart-failure
#3
Giuseppe Di Tano, Andrea Di Lenarda, Domenico Gabrielli, Nadia Aspromonte, Renata De Maria, Maria Frigerio, Massimo Iacoviello, Andrea Mortara, Adriano Murrone, Federico Nardi, Fabrizio Oliva, Roberto Pontremoli, Marino Scherillo, Michele Senni, Stefano Urbinati, Michele Massimo Gulizia
Sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is the first medication to demonstrate a mortality benefit in patients with chronic heart failure and reduced ejection fraction (HFrEF) since the early 2000s. Sacubitril/valsartan simultaneously suppresses renin-angiotensin-aldosterone system activation through blockade of angiotensin II type 1 receptors and enhances the activity of vasoactive peptides including natriuretic peptides, through inhibition of neprilysin, the enzyme responsible for their degradation...
October 2018: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/30276760/correction-to-do-limitations-in-the-design-of-paradigm-hf-justify-the-slow-real-world-uptake-of-sacubitril-valsartan-entresto
#4
Rosa Ahn, Vinay Prasad
The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below.
October 1, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/30266357/sacubitril-valsartan-the-newest-neurohormonal-blocker-for-guideline-directed-medical-therapy-for-heart-failure
#5
REVIEW
Ragavendra R Baliga
The burden of heart failure is projected to increase over the next decade; it is predicted that 1 in every 33 Americans will be affected by heart failure. Given that heart failure currently results in more than 1 million hospitalizations every year and the estimated 5-year mortality is approximately 50%, therapies that will improve survival and the economic burden are urgently needed. It is anticipated that the cost of managing heart failure is going to be approximately $70 billion in 2030. Therefore, the recent addition of the combination of sacubitril/valsartan (LCZ696) to guideline-directed medical therapies should ameliorate this burden...
October 2018: Heart Failure Clinics
https://www.readbyqxmd.com/read/30255725/reply-cost-effectiveness-of-sacubitril-valsartan-versus-enalapril-in-patients-with-heart-failure-and-reduced-ejection-fraction
#6
Lin Liang, David Bin-Chia Wu, Mohamed Ismail Abdul Aziz, Raymond Wong, David Sim, Kui Toh Gerard Leong, Yong Quek Wei, Doreen Tan, Kwong Ng
No abstract text is available yet for this article.
October 17, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/30214875/metabolic-effects-of-sacubitril-valsartan-are-they-relevant-in-clinical-practice
#7
EDITORIAL
Rafael de la Espriella-Juan, Juan Sanchis, Antoni Bayés-Genís, Julio Núñez
No abstract text is available yet for this article.
August 2018: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/30214874/sacubitril-valsartan-a-cardiovascular-drug-with-pluripotential-actions
#8
EDITORIAL
Steven G Chrysant, George S Chrysant
No abstract text is available yet for this article.
August 2018: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/30172655/a-drug-utilization-study-of-sacubitril-valsartan-in-catalonia
#9
Andrea Molina, Montse Vicente, Montse Gasol, Pere Carbonell, Pilar López, Caridad Pontes
No abstract text is available yet for this article.
August 29, 2018: Revista Española de Cardiología
https://www.readbyqxmd.com/read/30160656/sacubitril-valsartan-or-an-implantable-cardioverter-defibrillator-in-heart-failure-with-reduced-ejection-fraction-patients-a-cost-effectiveness-analysis
#10
Valerio Zacà
AIMS: The availability of novel drugs might affect the modern interplay between pharmacological and device therapy of heart failure with reduced ejection fraction (HFrEF). The aim of this study was to assess the cost-effectiveness of sacubitril/valsartan as compared with an implantable cardioverter-defibrillator (ICD) on top of optimal medical therapy in patients with HFrEF. METHODS: Data from 2000 adults with demographic and clinical characteristics similar to those in the PARADIGM-HF were derived as inputs for a four-state Markov model simulated HFrEF...
October 2018: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/30152839/usefulness-of-a-titration-algorithm-for-de-novo-users-of-sacubitril-valsartan-in-a-tertiary-centre-heart-failure-clinic
#11
Émilie Laflamme, Audrey Vachon, Sylvain Gilbert, Julie Boisvert, Vincent Leclerc, Mathieu Bernier, Pierre Voisine, Mario Sénéchal, Sébastien Bergeron
OBJECTIVE: A reduction in the rate of death and hospitalisations in patients with heart failure (HF) with reduced ejection fraction receiving sacubitril/valsartan compared to enalapril was demonstrated in the PARADIGM-HF study. However, tolerability when initiating and optimising sacubitril/valsartan treatment in real clinical practice is unknown. METHODS: We performed a prospective cohort study of clinical and biochemical parameters of the first 100 patients receiving sacubitril/valsartan in a tertiary HF clinic...
August 28, 2018: Cardiovascular Journal of Africa
https://www.readbyqxmd.com/read/30145973/-pharmacological-therapy-of-heart-failure-with-reduced-ejection-fraction
#12
Monika Wieser, Daniel Rhyner, Michele Martinelli, Thomas Suter, Bruno Schnegg, Claudia Bösch, Olivier Wigger, Stephan Dobner, Lukas Hunziker
Pharmacological therapy of heart failure with reduced ejection fraction Abstract. Pharmacological therapy for heart failure has made great progress over the last three decades and evidence-based therapies have significantly improved survival and quality of life. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers are the cornerstone of the heart failure therapy; indicated in virtually every patient with heart failure and reduced ejection fraction. As soon as the left ventricular ejection fraction decreases below 35 % and / or symptoms are still present (NYHA II-IV), a mineralocorticoid receptor antagonist should be added...
September 2018: Therapeutische Umschau. Revue Thérapeutique
https://www.readbyqxmd.com/read/30122239/sacubitril-valsartan-a-novel-angiotensin-receptor-neprilysin-inhibitor
#13
REVIEW
Ramesh R Dargad, Mahesh R Prajapati, Rohit R Dargad, Jai D Parekh
OBJECTIVE: To describe the efficacy, superiority and safety profile of the first-in-class angiotensin receptor-neprilysin inhibitor "Sacubitril/Valsartan" as compared to angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blocker (ARB) in heart failure (HF) patients, reviewing data available from both clinical and pre-clinical studies. Evidences on health care utilization outcomes such as hospitalizations and emergency department visits were also evaluated...
July 2018: Indian Heart Journal
https://www.readbyqxmd.com/read/30116284/sacubitril-valsartan-evaluation-of-safety-and-efficacy-as-an-antihypertensive-treatment
#14
REVIEW
Sarah L Anderson, Joel C Marrs
Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) that has garnered approval by the US Food and Drug Administration and the European Medicines Agency as a first-line treatment for heart failure with reduced ejection fraction...
2018: Drugs in Context
https://www.readbyqxmd.com/read/30114943/benefit-risk-review-of-different-drug-classes-used-in-chronic-heart-failure
#15
Gabriela Andries, Srikanth Yandrapalli, Wilbert S Aronow
Heart failure (HF) is an important public health problem with an increasing prevalence across the globe. The mortality rates from this complex clinical problem have stabilized in the recent years with the use of pharmacotherapeutics which demonstrated survival benefits in patients with HF with reduced ejection fraction (HFrEF). Areas covered: We reviewed the seven classes of medications which constitute the guideline-directed medical therapy (GDMT) in chronic HF patients. We discussed clinical trials which support or contradict their use, potential adverse events, and available real-world data on utilization and safety...
August 31, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/30093137/effect-of-sacubitril-valsartan-on-cardiac-filling-pressures-in-patients-with-left-ventricular-systolic-dysfunction
#16
Zubair Khan, Gunjan Gholkar, Sunit Tolia, Herman Kado, Marcel Zughaib
BACKGROUND: Sacubitril/valsartan is the newest neurohormonal agent approved for therapy in patients with heart failure with reduced ejection fraction (HFrEF). Little is known about its acute and incremental hemodynamic effects. We aimed to evaluate the change in hemodynamic profiles measured using an implanted monitoring device in HFrEF patients initiated on sacubitril/valsartan therapy. METHODS: We prospectively enrolled 13 subjects with HFrEF and pre-implanted CardioMEMS™ device on maximally tolerated guideline-directed medical therapy and no contraindications to sacubitril/valsartan therapy...
November 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/30084228/a-prospective-randomized-double-blind-placebo-controlled-pilot-study-of-sacubitril-valsartan-entresto-in-dogs-with-cardiomegaly-secondary-to-myxomatous-mitral-valve-disease
#17
Daniel K Newhard, SeungWoo Jung, Randolph L Winter, Sue H Duran
BACKGROUND: The effects of sacubitril/valsartan (S/V) on the renin-angiotensin-aldosterone system (RAAS) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD) are currently unknown. OBJECTIVES: To determine the pharmacodynamic effects of S/V on the RAAS, natriuretic peptide concentrations, systolic arterial pressure (SAP), tests of renal function, and serum electrolyte concentrations in dogs with cardiomegaly secondary to MMVD. ANIMALS: Thirteen client-owned dogs weighing 4-15 kg with American College of Veterinary Internal Medicine (ACVIM) Stage B2 MMVD...
September 2018: Journal of Veterinary Internal Medicine
https://www.readbyqxmd.com/read/30080749/interatrial-shunting-a-novel-device-based-therapy-for-patients-with-heart-failure
#18
Brian K W Yum, William H Frishman
Heart failure (HF) patients with either reduced ejection fraction or preserved ejection fraction experience a high mortality rate. The most recent pharmacologic advance for treating patients with HF with reduced ejection fraction has been with sacubitril/valsartan. Along with pharmaceutical research, there has been interest in device-based therapies as another treatment approach. One novel interventional device therapy that has shown promise in early tests and trials is the interatrial shunt device developed by Corvia Medical Inc...
September 2018: Cardiology in Review
https://www.readbyqxmd.com/read/30064356/the-cardiomems-system-in-the-clinical-management-of-end-stage-heart-failure-patients-three-case-reports
#19
Carsten Tschöpe, Alessio Alogna, Frank Spillmann, Alessandro Faragli, Gunther Schmidt, Florian Blaschke, Uwe Kühl, Ewa Hertel, Monika Willner, Daniel Morris, Heiner Post, Michel Noutsias, Burkert Pieske, Florian Krackhardt
BACKGROUND: Recent clinical trials have shown that pulmonary artery pressure-guided therapy via the CardioMEMS™ system reduces the risk of recurrent hospitalizations in chronic heart failure (HF) patients. The CardioMEMS™ pressure sensor is percutaneously implanted in a branch of the pulmonary artery and allows telemetric pressure monitoring via a receiver. According to the most recent ESC guidelines, this technology has currently a class IIb indication in patients with class III New York Heart Association symptoms and a previous hospitalization for congestive heart failure within the last year, regardless of ejection fraction...
July 31, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/30063443/newer-hormonal-pharmacotherapies-for-heart-failure
#20
Srikanth Yandrapalli, George Jolly, Medha Biswas, Yogita Rochlani, Prakash Harikrishnan, Wilbert S Aronow, Gregg M Lanier
Heart failure (HF) is characterized by maladaptive neurohormonal activation of the cardiovascular and renal systems resulting in circulatory inadequacy and frequent acute exacerbations. The increasing burden of HF prompted investigation of underlying pathophysiological mechanisms and the design of pharmacotherapeutics that would target these pathways. Areas covered: A MEDLINE search for relevant original investigations and review articles of newer hormonal drugs for HF since the year 2005 till October 2017 provided us with necessary literature...
January 2018: Expert Review of Endocrinology & Metabolism
keyword
keyword
161481
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"